ELITE PHARMACEUTICALS INC /NV/ Quarterly Depreciation in USD from Q2 2015 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Elite Pharmaceuticals Inc /Nv/ quarterly/annual Depreciation history and growth rate from Q2 2015 to Q3 2024.
  • Elite Pharmaceuticals Inc /Nv/ Depreciation for the quarter ending September 30, 2024 was $227K, a 30.5% decline year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ Depreciation for the twelve months ending September 30, 2024 was $1.21M, a 5.46% decline year-over-year.
  • Elite Pharmaceuticals Inc /Nv/ annual Depreciation for 2023 was $1.32M, a 6.69% increase from 2022.
  • Elite Pharmaceuticals Inc /Nv/ annual Depreciation for 2022 was $1.24M, a 3.58% increase from 2021.
  • Elite Pharmaceuticals Inc /Nv/ annual Depreciation for 2021 was $1.19M, a 8.06% decline from 2020.
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 $1.21M $227K -$99.9K -30.5% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 $1.31M $322K -$6.18K -1.88% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-14
Q1 2024 $1.32M $328K +$14K +4.45% Jan 1, 2024 Mar 31, 2024 10-K 2024-07-01
Q4 2023 $1.31M $337K +$22K +6.99% Oct 1, 2023 Dec 31, 2023 10-Q 2024-02-14
Q3 2023 $1.28M $327K +$11.2K +3.56% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 $1.27M $328K +$35.5K +12.1% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-14
Q1 2023 $1.24M $314K +$17.1K +5.76% Jan 1, 2023 Mar 31, 2023 10-K 2024-07-01
Q4 2022 $1.22M $315K +$21.6K +7.37% Oct 1, 2022 Dec 31, 2022 10-Q 2024-02-14
Q3 2022 $1.2M $316K +$20.5K +6.94% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $1.18M $293K -$16.4K -5.31% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 $1.19M $297K +$82.8K +38.6% Jan 1, 2022 Mar 31, 2022 10-K 2023-06-29
Q4 2021 $1.11M $293K -$213K -42.1% Oct 1, 2021 Dec 31, 2021 10-Q 2023-02-14
Q3 2021 $1.33M $295K +$40.4K +15.8% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 $1.28M $309K -$14.9K -4.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-15
Q1 2021 $1.3M $214K -$109K -33.6% Jan 1, 2021 Mar 31, 2021 10-K 2022-06-29
Q4 2020 $1.41M $506K +$179K +54.8% Oct 1, 2020 Dec 31, 2020 10-Q 2022-02-14
Q3 2020 $1.23M $255K -$73K -22.3% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-15
Q2 2020 $1.3M $324K -$3.34K -1.02% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-16
Q1 2020 $1.31M $323K +$11.6K +3.72% Jan 1, 2020 Mar 31, 2020 10-K 2021-06-14
Q4 2019 $1.29M $327K +$9.29K +2.93% Oct 1, 2019 Dec 31, 2019 10-Q 2021-02-16
Q3 2019 $1.28M $328K +$14.7K +4.71% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 $1.27M $327K +$27.2K +9.08% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $1.24M $312K -$27.7K -8.16% Jan 1, 2019 Mar 31, 2019 10-K 2020-06-30
Q4 2018 $1.27M $318K +$85.3K +36.7% Oct 1, 2018 Dec 31, 2018 10-Q 2020-02-10
Q3 2018 $1.19M $313K +$87.4K +38.6% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-12
Q2 2018 $1.1M $300K +$116K +62.6% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-09
Q1 2018 $982K $339K +$144K +73.6% Jan 1, 2018 Mar 31, 2018 10-K 2019-06-21
Q4 2017 $838K $232K +$65.8K +39.5% Oct 1, 2017 Dec 31, 2017 10-Q 2019-02-11
Q3 2017 $773K $226K +$60.2K +36.3% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 $712K $185K +$12.1K +7% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-09
Q1 2017 $700K $195K +$35.8K +22.4% Jan 1, 2017 Mar 31, 2017 10-K 2018-06-14
Q4 2016 $665K $167K -$7.31K -4.2% Oct 1, 2016 Dec 31, 2016 10-Q 2018-02-09
Q3 2016 $672K $166K +$5.02K +3.12% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-09
Q2 2016 $667K $173K +$14.6K +9.25% Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-09
Q1 2016 $652K $160K Jan 1, 2016 Mar 31, 2016 10-K 2018-06-14
Q4 2015 $174K Oct 1, 2015 Dec 31, 2015 10-Q 2017-02-09
Q3 2015 $161K Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-09
Q2 2015 $158K Apr 1, 2015 Jun 30, 2015 10-Q 2016-08-09
* An asterisk sign (*) next to the value indicates that the value is likely invalid.